Completed
Dose Escalation Study of Nintedanib (BIBF 1120) in Japanese Patients With Hepatocellular Carcinoma
NCT01594125
- Conditions
- Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +8 more
- Locations
-
- 1199.120.001 Boehringer Ingelheim Investigational Site Chuo-ku, Tokyo, Japan
- 1199.120.005 Boehringer Ingelheim Investigational Site Fukuoka, Fukuoka, Japan
- 1199.120.002 Boehringer Ingelheim Investigational Site Kashiwa, Chiba, Japan
- 1199.120.003 Boehringer Ingelheim Investigational Site Nagoya, Aichi, Japan